No Data
No Data
Alphamab Oncology's (HKG:9966) P/S Is Still On The Mark Following 91% Share Price Bounce
Hong Kong stocks fluctuate | Conic Jerry Pharmaceuticals-B (09966) soared more than 40%. HER2 dual-antibody ADC authorized cspc pharma. Involving a staggering 3.08 billion yuan investment.
Kangning Jeri Pharmaceuticals - B (09966) skyrocketed by over 40%, as of the press time, rose by 34.31%, trading at 4.11 Hong Kong dollars, with a turnover of 14.1032 million Hong Kong dollars.
HK stock announcement digs up | Nio Inc-SW(09866) obtains strategic investment of 3.3 billion yuan from investors in China.
Concordia Jerai Pharmaceuticals-B (09966) cooperates with cspc pharma on the development and commercialization of JSKN003 in mainland china; Guolian Securities (01456): The application for the acquisition of significant assets restructuring of Minsheng Securities has been accepted.
ALPHAMAB-B: 2024 INTERIM REPORT
Results of Alphamab's Clinical Trials Support Further Study of Anti-Cancer Drug JSKN003
The latest research results of the Phase I clinical study and Phase I/II clinical study of JSKN003 presented by Kangning Jerry Pharmaceutical-B (09966) at the 2024 ESMO conference.
CSPC Pharmaceutical Group Limited (09966) issued an announcement regarding the late-stage treatment of JSKN003 in Australia...
No Data
No Data